

I hereby certify that this correspondence is being hand-delivered in an envelope addressed to:
Examiner Teresa D. Wessendorf
United States Patent and Trademark Office
Art Unit 1639
1911 S. Clark Place
Crystal Mall One, 7th Floor
Arlington, VA 22202
703-308-3967

On: April 29, 2003

By: Robyn Errington

Printed Name: Robyn Errington

Attorney Docket No. 0155.130US
(formerly 18097-030310US)

COPY

RECEIVED
CENTRAL FAX CENTER

MAY 21 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen et al.

Application No.: 09/724,869

Filed: November 28, 2000

For: OPTIMIZATION OF
IMMUNOMODULATORY
PROPERTIES OF GENETIC
VACCINES

Examiner: Teresa D. Wessendorf

Art Unit: 1639

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §§ 1.97 AND 1.98**

Examiner Teresa D. Wessendorf
United States Patent and Trademark Office
Art Unit 1639
1911 S. Clark Place
Crystal Mall One, 7th Floor
Arlington, VA 22202

Dear Madam:

The references cited on attached form PTO/SB/08A-B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

COPY

Application No. 09/724,869
Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

By: 

Margaret A. Powers
Attorney for Applicant
Reg. No. 39,804

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560

COPY

(Modified) PTO/SB/08A-B (10-96)

Approve use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen, et al.
	Group Art Unit	1639
	Examiner Name	Teresa D. Wessendorf
	Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	5,718,883		Harlan et al.	02-17-1998	
	2	5,738,852		Robinson et al.	04-14-1998	
	3	5,858,778		Ostrand-Rosenberg et al.	01-12-1999	
	4	5,861,310		Freeman et al.	01-19-1999	
	5	6,071,716		Freeman et al.	06-06-2000	
	6	6,084,067		Freeman et al.	07-04-2000	
	7	6,149,905		Ostrand-Rosenberg et al.	11-21-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	8	WO	94/24267		Robinson, William S.	10-27-1994		
	9	WO	95/23859		Brigham & Women's Hospital; Dana-Farber Cancer Institute	09-08-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).		T
	10	Fargeas, C.A., et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA-4," Journal of Experimental Medicine 182(3):667-675 (1995)		
	11	Freeman, G.J. et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation," Science 262:909-911 (1993)		
	12	Guo, Y., et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA-4 binding Site on Immunoglobulin C-like Domain," Journal of Experimental Medicine 181(4):1345-1355 (1995)		
	13	He, X-S. et al., "Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen," Proc. Natl. Acad. Sci. USA 93:7274-7278 (1996)		
	14	Kim, J.J. et al., "Engineering DNA Vaccines via Co-delivery of Co-Stimulatory Molecule Genes," Vaccine 16(19):1828-1835 (1998)		
	15	Kuchroo, V.K. et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707-718 (1995)		
	16	Metzler, W., et al., "Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28," Nature Structural Biology 4(7):527-531 (July 1997)		
	17	Parsons, K.R., et al., "Cloning of Cattle CD80," Immunogenetics 49(3):231-234 (1999)		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

(Modified) PTO/SB/08A-B (10-96)

Approv. : use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen, et al.
	Group Art Unit	1639
	Examiner Name	Teresa D. Wessendorf
	Attorney Docket Number	0155.130US

18	Peach, R.J., et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28," Journal of Biological Chemistry 270(36):21181-21187 (1995)	
19	Rennert, P. et al., "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion," International Immunology 9(6):805-813 (1997)	
20	Wu, Y., "CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997)	

**RECEIVED
CENTRAL FAX CENTER****MAY 21 2007**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

PLACE
STAMP
HERE

RECEIVED
TECH CENTER 1600/2900
03 APR 29 PM 1:22

Margaret A. Powers
Maxygen, Inc.
Intellectual Property Dept.
515 Galveston Drive
Redwood City, CA 94063

MAY 21 2007

COPY

SERIAL NO: 09/724,869 DATE FILED: 28-Nov-2000 DKT. NO.: 0155.130US ATTY: MAP
TITLE: Optimization of Immunomodulatory Properties of Genetic Vaccines
APPLICANT: Juha Punnonen, et al. DATE HAND DELIVERED: April 29, 2003
☐ CERTIFICATE OF MAILING ☐ EXPRESS MAIL LABEL NO.

THE U.S. PATENT AND TRADEMARK OFFICE ACKNOWLEDGES RECEIPT OF:

- ☒ Auth. To Charge Deposit Account No. 50-0990
- ☒ Supplemental Information Disclosure Statement (2 pgs)
- ☒ Form 1449 with (20) References
- ☒ Receipt

Examiner Teresa D. Wessendorf
U.S. Patent & Trademark Office
Art Unit 1639
911 S. Clark Pl., Crystal Mall One
7th Floor
Arlington, VA 22202
HAND CARRY

